Women undergoing lumpectomies to remove tumors or breast cancer are faced with limited options if they are unhappy with the physical outcome of their breast: spend months filling the void with a series of fat injections, which then have the potential to be reabsorbed into the body; or do nothing, which can leave breasts disfigured and asymmetrical.
TeVido BioDevices is an early-stage life sciences/biotech company using 3D bio-printing of live cells to build custom implants and grafts for breast cancer reconstruction.
Globally, in 2010, there were ~ 1 million incidences of breast cancer. In 2013, nearly 300,000 women in the US will be diagnosed, with 50-60% of them choosing a lumpectomy as part of the treatment regime. Of those, at least 25% are dissatisfied with the physical outcome of the remaining breast tissue and those women were far more likely to experience symptoms of depression and fear of cancer recurrence compared to women with minimal asymmetry. However few reconstructive options exist for lumpectomies. TeVido is developing a natural implant, from a woman’s own fat cells, for this indication.
Longer term, TeVido’s solution for lumpectomies could expand to the broader and more lucrative market for breast augmentation which is estimated at $10 Billion in the US. An adjacent market exists for soft tissue reconstruction for other conditions such as sport and war related injuries resulting in tissue deficiency as well as the rare soft tissue sarcomas of the extremities. These conditions have significant quality of life impacts for the patient.